S&P 5007,683.69▼0.8% Nasdaq26,820.38▼0.9% Dow51,481.51▼0.7% Russell 2K2,817.91▼0.7% 10-Yr5.24%+6bp VIX16.07+1.20 WTI$93.42▲1.1% Gold$4,147.50▼4.0% EUR/USD1.137▼0.1% BTC$84,270▲0.8% Nikkei65,339▼1.6%
At close · Tue, Sep 29, 2026
Daily Market Updates.

US Markets

Home›US Markets›Sectors›Lilly tests an amylin drug as a GLP-1-like option for…

Lilly tests an amylin drug as a GLP-1-like option for weight loss

The experimental amylin approach is being developed for weight loss and diabetes management, similar to GLP-1 drugs.

Reported · Written up by our desk · Sectors

Lilly is working on an experimental amylin drug aimed at helping people lose weight and manage diabetes, a goal similar to GLP-1 medications, according to MarketWatch.

The coverage also notes that add-on outcomes tied to a newer weight loss drug were associated with weight reductions of up to 23%, while also coming with more side effects.

MarketWatch said Lilly is evaluating the experimental amylin treatment as part of that broader effort to improve outcomes for obesity and diabetes patients.

← Newer storyEli Lilly plans Phase 3 for combo obesity regimen later this year

More like this

US MarketsYoung Americans increasingly launch businesses as job market tightens
US MarketsEpic engineers use Anthropic AI tool to flag patient data security risks
US MarketsStrategists point to a threat beyond bond-yield fears for stocks
US MarketsIndianOil, Sanofi India among firms with volatile dividend payouts
US MarketsMcDonald's uses AI to set “optimal price” for menu items per location

Sources

MarketWatchAdding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
MarketWatchAdding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.